Chimeric antigen receptor T-cell therapy – assessment and management of toxicities.
Neelapu SS et al. Nat Rev Clin Oncol. 2017 Sep 19. doi: 10.1038/nrclinonc.2017.148. [Epub ahead of print].

Chimeric Antigen Receptor T-cell Therapies for Multiple Myeloma.
Mikkilineni L et al. Blood. 2017 Sep 19. pii: blood-2017-06-793869. doi: 10.1182/blood-2017-06-793869. [Epub ahead of print].

Checking in: T cells against multiple myeloma.
Kumar SK. Blood. 2017 Sep 7;130(10):1175-1176. doi: 10.1182/blood-2017-05-783647.

Adoptive cell therapy in multiple Myeloma.
Vallet S et al. Expert Opin Biol Ther. 2017 Sep 6:1-12. doi: 10.1080/14712598.2017.1375095. [Epub ahead of print].

Advances in immunotherapy in multiple myeloma.
Boussi L et al. Curr Opin Oncol. 2017 Sep 4. doi: 10.1097/CCO.0000000000000407. [Epub ahead of print].

Facts and Hopes in Immunotherapy of Lymphoma and Myeloma.
Pianko MJ et al. Clin Cancer Res. 2017 Sep 12. pii: clincanres.0539.2017. doi: 10.1158/1078-0432.CCR-17-0539. [Epub ahead of print].

From a Better Understanding of the Mechanisms of Action of Histone Deacetylases Inhibitors to the Progress of the Treatment of Malignant Lymphomas and Plasma Cell Myeloma.
Mihăilă RG. Recent Pat Anticancer Drug Discov. 2017 Sep 19. doi: 10.2174/1574892812666170920110054. [Epub ahead of print].

Discovery and application of immune biomarkers for hematological malignancies. 
Zafeiris D et al. Expert Rev Mol Diagn. 2017 Sep 19. doi: 10.1080/14737159.2017.1381560. [Epub ahead of print].

Identification of novel targets for multiple myeloma through integrative approach with Monte Carlo cross-validation analysis.
Liu C et al. J Bone Oncol. 2017 Aug 12;8:8-12. doi: 10.1016/j.jbo.2017.08.001. eCollection 2017 Sep.

Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
Ettari R et al. Pharmacol Ther. 2017 Sep 11. pii: S0163-7258(17)30235-8. doi: 10.1016/j.pharmthera.2017.09.001. [Epub ahead of print].

A New Monoclonal Protein Detected in a Patient With MyelomaUndergoing Elotuzumab Therapy.
Tang F et al. JAMA Oncol. 2017 Sep 7. doi: 10.1001/jamaoncol.2017.2665. [Epub ahead of print].

Pomalidomide desensitization in a patient hypersensitive to immunomodulating agents.
Seki JT et al. Curr Oncol. 2017 Aug;24(4):e328-e332. doi: 10.3747/co.24.3572. Epub 2017 Aug 31.

FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
Bhatnagar V et al. Oncologist. 2017 Sep 13. pii: theoncologist.2017-0229. doi: 10.1634/theoncologist.2017-0229. [Epub ahead of print].

Real-life experience with bortezomib-based regimens in elderly comorbid patients with newly diagnosed multiple myeloma – Polish retrospective multicenter analysis.
Hus I et al. Pol Arch Intern Med. 2017 Sep 14. doi: 10.20452/pamw.4099. [Epub ahead of print].

Symptom experience of multiple myeloma (syMMex) patients treated with autologous stem cell transplantation following high-dose melphalan: a descriptive longitudinal study.
Naegele M et al. Support Care Cancer. 2017 Sep 16. doi: 10.1007/s00520-017-3897-z. [Epub ahead of print].

Everyday life following hematopoietic stem cell transplantation: decline in physical symptoms within the first month and change-related predictors.
Kroemeke A et al. Qual Life Res. 2017 Sep 12. doi: 10.1007/s11136-017-1705-3. [Epub ahead of print].

Treatment-free Interval as a Metric of Patient Experience and a Health Outcome of Value for Advanced Multiple Myeloma: The Case for the Histone Deacetylase Inhibitor Panobinostat, a Next-generation Novel Agent.
Richardson P et al. Expert Rev Hematol. 2017 Sep 8. doi: 10.1080/17474086.2017.1369399. [Epub ahead of print].

Free Immunoglobulin Light Chains as Criteria of Extracorporeal Hemocorrection in Patients with Monoclonal Gammopathies.
Lyubimova NV et al. Bull Exp Biol Med. 2017 Aug;163(4):493-496. doi: 10.1007/s10517-017-3836-5. Epub 2017 Aug 29.

Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes.
Shah JJ et al. Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):575-583.e2. doi: 10.1016/j.clml.2017.06.013. Epub 2017 Jun 17.

A Benefit Risk Analysis Approach To Capture Regulatory Decision-Making: Multiple Myeloma.
Raju GK et al. Clin Pharmacol Ther. 2017 Sep 13. doi: 10.1002/cpt.871. [Epub ahead of print].

Novel therapies for multiple myeloma.
Wallington-Beddoe CT et al. Aging (Albany NY). 2017 Aug 28;9(8):1857-1858. doi: 10.18632/aging.101284.

Managing multiple myeloma in elderly patients.
Diamond E et al. Leuk Lymphoma. 2017 Aug 28:1-12. doi: 10.1080/10428194.2017.1365859. [Epub ahead of print].

IgE monoclonal gammopathy: A case report and literature review.
Hejl C et al. Clin Biochem. 2017 Sep 20. pii: S0009-9120(17)30591-X. doi: 10.1016/j.clinbiochem.2017.09.015. [Epub ahead of print].

Myeloma and Bone Disease.
Panaroni C et al. Curr Osteoporos Rep. 2017 Aug 31. doi: 10.1007/s11914-017-0397-5. [Epub ahead of print].

Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines.
Stacul F et al. Eur Radiol. 2017 Aug 30. doi: 10.1007/s00330-017-5023-5. [Epub ahead of print].